Namocell has partnered with the two firms to distribute its cell dispensing tool in South Korea, the Netherlands, Belgium, and Luxembourg.
The firm will use the proceeds to accelerate commercialization and deployment of its microfluidic technology and for working capital purposes.
The firm will use the net proceeds to advance commercialization of its microfluidic technology and for general corporate purposes.
Tomy Digital Biology has agreed to distribute Namocell's microfluidic-based cell platforms in the Japanese market.
The funding totals up to $5.6 million over five years and will incorporate Talis' proprietary SlipChip technology.
The Alameda, California-based startup will use the funding to advance the commercialization of its rapid diagnostic platform for infectious diseases.
The firm's microfluidic-based technology collects and purifies genetic material, causing a complete PCR reaction that identifies diseases in liquid samples.
Given the high yield of miRNA markers they were able to isolate, the researchers believe the approach could be commercialized for routine cancer testing.
The firm will begin initial trials for antibiotic-resistant urinary tract infection detection in UK hospitals in early 2018.
The firm plans to expedite cell sorting for research labs with an inexpensive device that uses piezoelectric actuators and disposable microfluidics.
National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.
NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.
The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.
In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.